For US biotechs that have already secured FDA approval, entering the EU and UK is no longer a question of generating new data. It becomes a question of how that data is presented, interpreted, and assessed within a different regulatory framework.
While much of the core dossier can be leveraged, EU and UK regulatory submissions introduce additional procedural and strategic complexity. Different submission pathways, authority interactions, and documentation expectations can create delays if they are not anticipated early.
Yet the fundamental challenge is rarely scientific. It is organisational. Companies must translate an FDA-oriented dossier into the expectations of European regulators while managing new procedural dynamics.
In this blog post, we explore:
- how to select the appropriate regulatory pathway for EU and UK submissions
- how to translate an FDA dossier into EU and UK regulatory expectations
- how authority interactions differ during European regulatory assessments
- how disciplined execution helps control submission timelines
Start with the Right Submission Pathway
In Europe, the choice of regulatory pathway is not a formality. It determines how a product will be assessed, which authorities are involved, and how review timelines are structured.
The centralised procedure, managed by the European Medicines Agency (EMA), is mandatory for certain product types, including biotechnology-derived products. This pathway leads to a single marketing authorisation valid across all EU Member States.
Other products may follow decentralised or mutual recognition procedures, depending on product characteristics and strategic considerations.
In the United Kingdom, following Brexit, submissions are handled independently by the Medicines and Healthcare Products Regulatory Agency (MHRA), with its own procedures and timelines.
For US biotechs, the key is to align the chosen regulatory pathway with both the product profile and the commercial strategy early. This decision determines:
- the structure of the submission dossier
- the authorities involved in the assessment
- expected review timelines
- the coordination required between EU and UK processes
Selecting the correct pathway early significantly reduces downstream regulatory complexity.
Translating the FDA Dossier into EU and UK Expectations
Although the Common Technical Document (CTD) format is shared globally, regulatory interpretation differs across regions.
EU and UK regulators expect a clear justification of how a product meets local regulatory standards, particularly in areas such as benefit–risk assessment, quality documentation, and pharmacovigilance planning.
As a result, an FDA dossier cannot simply be reused without adaptation.
Key areas that typically require attention include:
- Quality (Module 3) — Demonstrating that manufacturing processes, control strategies, and specifications comply with EU GMP expectations.
- Clinical and Non-Clinical Summaries (Modules 2.4–2.7) — Ensuring consistency in how benefit–risk is evaluated and presented.
- Risk Management Plan (RMP) — A mandatory EU pharmacovigilance requirement that differs from US safety frameworks.
The objective is not to duplicate work, but to ensure that existing data is presented in a narrative that aligns with European regulatory logic rather than US-centric assumptions.
How Regulatory Authorities Interact During Assessment
One of the most important differences between FDA and EU/UK submissions lies in how regulatory interactions are structured during the review process.
Within the centralised procedure, the EMA coordinates the assessment through rapporteurs from EU Member States. The evaluation follows structured assessment cycles with predefined timelines.
Questions from regulators are issued as formal lists of questions, and responses must be carefully coordinated to maintain consistency across the entire dossier.
In the UK, the MHRA follows an independent assessment process, with its own review milestones and clarification mechanisms.
For companies unfamiliar with these procedures, the key risk lies in underestimating the complexity of response management.
Regulatory questions rarely concern a single issue. They often reflect broader concerns that require coordinated answers across regulatory, clinical, quality, and manufacturing functions.
Establishing a clear governance model for authority interactions is therefore essential. This typically includes:
- defining ownership of regulatory responses
- aligning cross-functional contributions
- maintaining strict version control of the dossier
- coordinating messaging across modules
Without this governance, response cycles can quickly become inefficient and delay the overall review process.
Controlling Timelines Through Execution Discipline
Regulatory timelines in the EU and UK follow structured review frameworks, but delays frequently occur.
In many cases, these delays are not driven by regulators but by the sponsor's ability to respond effectively to assessment questions.
Typical execution risks include:
- fragmented ownership of regulatory responses
- inconsistent messaging across dossier modules
- late identification of documentation gaps
- underestimation of translation and administrative requirements
A disciplined execution model is therefore essential.
This means planning response cycles early, aligning internal stakeholders, and ensuring that supporting documentation is prepared before submission.
Particular attention should also be given to Module 1 administrative content, including labelling, application forms, and region-specific regulatory elements. Deficiencies in this module can delay dossier validation before the scientific assessment even begins.
Aligning EU and UK Submissions Without Forcing a Single Process
There are clear efficiencies in aligning EU and UK regulatory submissions. However, treating both processes as identical can create unnecessary friction.
The most effective approach is typically a shared technical core combined with procedural flexibility.
Under this model:
- the scientific and technical dossier remains aligned
- procedural elements are managed separately
- submission platforms and authority expectations are respected
- timelines are coordinated without forcing identical processes
This dual-track approach reduces operational complexity and helps avoid last-minute adjustments driven by procedural differences.
Closing Remarks: Turning EU and UK Submissions into a Structured Extension of Development
For US biotechs entering Europe, the submission phase is rarely about generating new evidence. Instead, it focuses on ensuring that existing data is presented, justified, and managed in a way that aligns with EU and UK regulatory systems. Success depends on three critical elements:
- selecting the appropriate regulatory pathway
- translating the FDA dossier into European regulatory expectations
- maintaining disciplined execution throughout the assessment process
When these elements are in place, EU and UK submissions become a structured extension of the development program rather than a source of uncertainty or delay.
关于作者
PhD · Global Head Regulatory Affairs at QbD Group
Angeles has built her career at the crossroads of science and regulation. From academic research at CNB and CNIC to leadership roles in biotech and global consulting firms like Asphalion, Parexel, Pharmalex, and Scendea, she translates regulatory complexity into action. She has a strong track record of building and scaling teams, and is especially focused on the intersection of data, AI, and regulation to unlock faster healthcare innovation.
End-to-End Support from Strategy to First-in-Human
We support emerging biotech teams with integrated regulatory, quality, CMC, and safety expertise, built for speed without compromising credibility.
Read more
